Credit Suisse Sets Bearish Tone For Amgen; Says Current Setup Not Ideal For Growth
Credit Suisse has initiated coverage on Amgen Inc (NYSE:AMGN) with an Underperform rating and a price target of $240. The analysts say…
Credit Suisse Sees Uncertainty On New Product Launch Execution & Growth For Bristol Myers
Credit Suisse has initiated coverage on Bristol-Myers Squibb Co (NYSE:BMY) with a Neutral rating and a price target of $78. The analysts…
Credit Suisse Says AbbVie’s Humira Patent Cliff Could Provide Momentum to Boost Growth
Credit Suisse has initiated coverage on AbbVie Inc (NYSE:ABBV) with an Outperform rating and a price target of $170. AbbVie stands on…
Eli Lilly Is Best-In-Class Growth, Says Analyst While Initiating Coverage
Credit Suisse has initiated coverage on Eli Lilly And Co (NYSE:LLY) with an Outperform rating and a price target of $395. Management…
Credit Suisse Believes In This Pharma Giant’s Low Risk Growth Against Uncertain Backdrop
Credit Suisse has initiated coverage on Merck & Co Inc (NYSE:MRK) with an Outperform rating and a price target of $120. The…
HC Wainwright Creates Bullish Pitch On 4D Molecular Citing ‘Broader Systemic Potential’
HC Wainwright has initiated coverage on 4D Molecular Therapeutics Inc (NASDAQ:FDMT) with a price target of $36 and a Buy rating. The…
Morgan Stanley Assumes Ross Stores at Overweight, Raises Price Target to $127
Morgan Stanley analyst Kimberly Greenberger assumes Ross Stores (NASDAQ:ROST) with a Overweight rating and raises Price Target to $127.
Cantor Fitzgerald Initiates Coverage On Precigen with Overweight Rating, Announces Price Target of $7
Cantor Fitzgerald analyst Jennifer Kim initiates coverage on Precigen (NASDAQ:PGEN) with a Overweight rating and announces Price Target of $7.
Raymond James Initiates Coverage On Fulgent Genetics with Outperform Rating, Announces Price Target of $45
Raymond James analyst Andrew Cooper initiates coverage on Fulgent Genetics (NASDAQ:FLGT) with a Outperform rating and announces Price Target of $45.